Bavarian Nordic announced a new collaboration that will investigate CV301, the Company’s targeted immunotherapy candidate, and durvalumab (IMFINZITM), AstraZeneca‘s PD-L1 inhibitor, in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancers.    Under the collaboration with Georgetown University, both Bavarian Nordic and AstraZeneca will contribute clinical trial material and provide financial support for a planned Phase 1/2 clin...